SML3670

Raltegravir

≥98% (HPLC), HIV-1 integrase inhibitor , powder

• Synonim(y): MK 0518, MK-0518, MK0518, N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxamide
• Wzór empiryczny (zapis Hilla): C₂₀H₂₁FN₆O₅
• Numer CAS: 518048-05-0
• Masa cząsteczkowa: 444.42
• UNSPSC Code: 51111800
• NACRES: NA.25
• MDL number: MFCD10698872
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Nazwa produktu: Raltegravir, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: Fc1ccc(cc1)CNC(=O)C2N=C(N(C(=O)C2=O)C)C(NC(=O)c3nnc([o]3)C)(C)C
• InChI: 1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,13H,9H2,1-4H3,(H,22,29)(H,24,30)
• InChI key: DDGPCENTWMZXFO-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

Orally active, potent and selective HIV type-1 (HIV-1) integrase inhibitor in cultures and in vivo.

Raltegravir (MK-0518) is an orally active, potent and selective HIV type-1 (HIV-1) integrase inhibitor (IC50 = 2-7 nM; ineffctive against HIV-1 reverse transcriptase or protease) that prevents HIV-1 cellular replication by blocking viral cDNA integration into host genome in cultures (IC50 = 19 nM & 33 nM in the presence of 10% fetal bovine serum or 50% human serum) and in vivo.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable